Basic Information
Tygacil
Regulatory Information
EMEA/H/C/000644
April 24, 2006
35
March 6, 2025
Company Information
Belgium
Boulevard de la Plaine 17 1050 Bruxelles
Pfizer Europe MA EEIG
Active Substances Detail
EMA Resources
Detailed Information
Therapeutic Indication
### Therapeutic indication Tygacil is indicated in adults and in children from the age of eight years for the treatment of the following infections: - Complicated skin and soft tissue infections (cSSTI), excluding diabetic foot infections - Complicated intra-abdominal infections (cIAI) Tygacil should be used only in situations where other alternative antibiotics are not suitable. Consideration should be given to official guidance on the appropriate use of antibacterial agents. appropriate use of antibacterial agents.
Overview Summary
This is a summary of the European public assessment report (EPAR) for Tygacil. It explains how the Committee for Medicinal Products for Human Use (CHMP) assessed the medicine to reach its opinion in favour of granting a marketing authorisation and its recommendations on the conditions of use for Tygacil.